Trulicity (Dulaglutide) Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

Why Dulaglutide Affects Anesthetic Safety

Dulaglutide acts on GLP-1 receptors in the gut and the central nervous system to slow gastric motility, reduce appetite, and lower postprandial glucose. Those same mechanisms become a surgical hazard when a patient is sedated. Gastric contents that have not emptied normally can be aspirated into the lungs during induction or emergence from anesthesia, causing aspiration pneumonitis or pneumonia.

The Gastric Emptying Mechanism

GLP-1 receptor agonists reduce the rate at which the stomach empties into the duodenum. A 2022 scintigraphy study published in Diabetes Care showed that semaglutide 1 mg weekly delayed gastric emptying of a solid meal by roughly 30% versus placebo at steady state [1]. Dulaglutide shares this pharmacodynamic class effect. Because gastric emptying delay is proportional to GLP-1 receptor occupancy, once-weekly formulations like Trulicity maintain receptor engagement throughout the dosing interval, meaning the effect does not simply "wear off" a day or two before surgery.

What "Delayed Gastric Emptying" Means in Practice

Under normal fasting conditions, the stomach empties a standard meal in 4 to 6 hours. Patients on dulaglutide may retain food or fluid in the stomach well beyond that window even after a conventional 8-hour fast [2]. Retained gastric contents during intubation or airway instrumentation can reflux into the pharynx and be aspirated. Aspiration pneumonitis carries a mortality rate of approximately 5% when it progresses to acute respiratory distress syndrome [3].

GLP-1 Receptor Agonist Half-Life and Surgery Planning

Dulaglutide has a terminal half-life of approximately 5 days [4]. After a single omitted weekly dose, plasma concentrations fall by roughly 50% at day 5 and to about 25% of peak by day 10. This pharmacokinetic profile means a one-week hold reduces, but does not eliminate, pharmacological gastric motility suppression. Anesthesiologists often treat patients who have taken their last dulaglutide dose 6 or fewer days before surgery as potentially having a "full stomach," warranting a rapid sequence induction.

The 2023 ASA Advisory: What It Says and Why It Matters

The American Society of Anesthesiologists issued a patient safety advisory in June 2023 addressing GLP-1 receptor agonists specifically. The advisory states that patients taking weekly GLP-1 RAs should hold the medication for one full dosing cycle (7 days) before any elective procedure requiring general anesthesia or deep sedation [5].

Text of the Recommendation

The ASA advisory specifies: "If GLP-1 agonists are used for diabetes management (any dose), consider holding the medication on the day of the procedure for daily doses, and a week prior for weekly formulations" [5]. For patients on GLP-1 RAs for weight management only, the advisory recommends holding for one week regardless of frequency. This language directly applies to dulaglutide, which is dosed once weekly.

Levels of Sedation Covered

The ASA advisory covers general anesthesia, neuraxial anesthesia with sedation, and moderate to deep procedural sedation. Topical or minimal sedation procedures (for example, simple dental work under local anesthesia only) may carry lower risk, but the anesthesiologist makes this judgment on a case-by-case basis.

When Elective Surgery Cannot Be Delayed

Patients who arrive for surgery having taken dulaglutide within the past 7 days should be evaluated with a point-of-care gastric ultrasound when available. A gastric antrum cross-sectional area above 340 mm² in the right lateral decubitus position suggests a full stomach in adults [6]. If ultrasound is unavailable and cancellation is not feasible, rapid sequence induction with cricoid pressure is the standard fallback, though cricoid pressure efficacy remains debated in current literature.

Aspiration Risk: Evidence From the Literature

The 2023 ASA advisory was preceded by a wave of case reports and pharmacovigilance signals. A letter published in Anaesthesia in 2023 described four patients on semaglutide who had unexpected retained gastric contents confirmed on upper gastrointestinal endoscopy after standard preoperative fasting [7]. Endoscopists noted solid food residue averaging 12 hours post-ingestion. While those cases involved semaglutide, the mechanism is identical for dulaglutide given the shared GLP-1 receptor agonism.

FDA Label Language on Gastroparesis

The Trulicity prescribing information states that dulaglutide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in that population [4]. This label language is clinically significant: patients with pre-existing gastroparesis who take dulaglutide face additive gastric stasis, amplifying perioperative risk substantially.

Risk Stratification by Procedure Type

Not all procedures carry the same aspiration hazard. The table below outlines a practical risk-stratification approach.

| Procedure Type | Airway Management | Aspiration Risk Level | Suggested Hold | |---|---|---|---| | General anesthesia (elective) | Endotracheal tube or LMA | High | 7 days | | Deep sedation (endoscopy, colonoscopy) | Natural airway, unprotected | Moderate-high | 7 days per ASA | | Moderate sedation (minor procedures) | Natural airway | Moderate | Discuss with anesthesiologist | | Local/topical only | None | Low | Not routinely required | | Emergency surgery | Any | Variable | RSI; gastric ultrasound if feasible |

Perioperative Blood Glucose Management When Dulaglutide Is Held

Holding dulaglutide for 7 days before surgery removes a meaningful glucose-lowering agent from the regimen of patients with type 2 diabetes. Blood glucose control in the perioperative period is directly linked to outcomes: the ADA Standards of Medical Care in Diabetes 2024 recommend maintaining glucose between 140 and 180 mg/dL in most hospitalized patients, citing evidence that hyperglycemia above 180 mg/dL increases surgical site infections, prolonged hospital stay, and 30-day mortality [8].

Bridging Strategies

When dulaglutide is held preoperatively, the prescribing physician should assess whether the patient needs bridging therapy. Options include:

• Continuation of baseline oral agents such as metformin up to the morning of surgery for low-contrast, low-risk procedures (per ADA guidance)
• Addition of basal insulin (for example, insulin glargine at a reduced dose of 50 to 80% of the home dose) for patients whose A1C exceeds 8% or whose fasting glucose consistently runs above 160 mg/dL
• Intraoperative glucose monitoring every 1 to 2 hours with correction using a sliding scale of regular insulin or an insulin infusion protocol for procedures lasting more than 2 hours

Postoperative Resumption

Dulaglutide can typically be restarted once the patient is tolerating oral intake without nausea, has stable bowel function, and does not have an ileus. For most elective abdominal surgeries, this is 2 to 4 days postoperatively. Cardiac, orthopedic, and other non-abdominal procedures often allow resumption within 24 to 48 hours if the patient is eating normally. The restarted dose is the patient's pre-hold maintenance dose; no titration restart is needed because dulaglutide does not lose receptor sensitivity after a one-week break.

Alcohol and Dulaglutide: A Separate Perioperative Consideration

The question of whether patients can drink alcohol while on Trulicity surfaces frequently in preoperative consultations. Alcohol is not absolutely contraindicated with dulaglutide, but the combination produces three overlapping concerns that are relevant in the surgical preparation window.

Hypoglycemia Amplification

Alcohol inhibits hepatic gluconeogenesis. In patients taking dulaglutide alongside sulfonylureas or insulin, alcohol consumption may deepen and prolong hypoglycemic episodes [4]. A blood glucose below 70 mg/dL in the 12 hours before surgery complicates anesthetic management and may require oral or intravenous glucose supplementation, delaying the procedure.

Gastrointestinal Symptom Overlap

Dulaglutide's most common adverse effects are nausea, vomiting, and abdominal discomfort, reported in 12 to 21% of patients during dose escalation in the AWARD-1 trial (N=978) [9]. Alcohol independently irritates the gastric mucosa and can intensify these symptoms. A patient who has been drinking heavily in the days before surgery may present with nausea that confounds assessment of medication tolerance and further increases aspiration risk.

Preoperative Instructions

Patients should be counseled to avoid alcohol for at least 24 hours before any procedure requiring anesthesia, independent of their GLP-1 RA status. The combination of dulaglutide-induced gastric stasis and alcohol-induced gastric irritation represents an additive risk for perioperative nausea and vomiting (PONV), which itself is a risk factor for aspiration during recovery.

Preoperative Checklist: Coordinating the Dulaglutide Hold

The following protocol consolidates ASA guidance, FDA label data, and ADA perioperative standards into a stepwise preoperative checklist for patients on dulaglutide.

Step 1 (At least 14 days before surgery): The prescribing clinician and surgical team confirm the procedure date and identify all glucose-lowering medications. Dulaglutide is flagged as requiring a 7-day hold.

Step 2 (Day 7 before surgery): Patient skips the weekly dulaglutide injection. A written reminder from the prescriber or pharmacy helps prevent inadvertent dosing.

Step 3 (Day 3 to 5 before surgery): Fasting glucose is measured. If values exceed 180 mg/dL consistently, the prescriber adjusts oral agents or initiates basal insulin bridging. Alcohol is discontinued at this point.

Step 4 (Day of surgery): Patient follows standard NPO instructions (nothing by mouth for at least 8 hours for solids; clear liquids allowed up to 2 hours before induction per ASA fasting guidelines [10]). The anesthesiologist is informed of the GLP-1 RA hold date. Gastric ultrasound is performed if the most recent dulaglutide dose was fewer than 7 days ago.

Step 5 (Post-procedure): Blood glucose is monitored every 2 hours until oral intake resumes. Dulaglutide is restarted at the maintenance dose once the patient is eating without difficulty and nausea has resolved.

Drug-Drug Interactions Beyond Anesthesia

Dulaglutide's gastric emptying delay affects the absorption kinetics of orally administered co-medications, a consideration that extends into the perioperative window.

Oral Medications With Narrow Therapeutic Windows

Drugs with narrow therapeutic indices and time-sensitive absorption profiles (for example, cyclosporine, warfarin, and certain antiepileptics) may show altered peak plasma concentrations in patients on dulaglutide. The Trulicity prescribing information notes that drugs dependent on threshold concentrations for efficacy should be taken with caution and monitored closely [4]. Warfarin INR should be checked within 5 to 7 days of starting dulaglutide or adjusting its dose.

Oral Antibiotics Given Perioperatively

Prophylactic antibiotics such as cefazolin are administered intravenously for most surgical procedures, bypassing the gastric emptying issue. However, patients discharged on oral antibiotics (for example, amoxicillin-clavulanate after certain outpatient procedures) may absorb them more slowly while restarting dulaglutide postoperatively. Prescribers should consider this when setting dosing schedules.

Metformin Co-Administration

Metformin and dulaglutide are frequently co-prescribed. The AWARD-10 trial (N=424) showed that the combination reduced A1C by 1.3 percentage points versus 0.5 percentage points for placebo added to metformin over 26 weeks [11]. In the perioperative setting, metformin carries its own hold requirement for procedures involving iodinated contrast media or those with expected hemodynamic instability, creating a dual-hold situation that should be addressed explicitly at the preoperative visit.

Communicating the Risk to Patients

Clear, jargon-free communication improves adherence to the hold protocol. Patients often do not recognize that a once-weekly injectable medication for diabetes has anything to do with anesthesia safety. A practical explanation might run as follows: "Trulicity slows the speed at which your stomach empties food into your intestines. That is useful day-to-day, but during surgery you need your stomach to be empty so that food cannot get into your lungs while you are under anesthesia. Skipping one injection a week before surgery lets your stomach return closer to its normal speed."

Written instructions, confirmed by a callback from the prescribing clinic 5 to 7 days before the procedure, reduce the likelihood of a patient showing up for surgery having taken the medication on schedule without realizing the hold was required.

Special Populations

Patients With Type 2 Diabetes and Existing Gastroparesis

These patients should not be on dulaglutide in the first place, per the FDA label [4]. If a patient with known diabetic gastroparesis is found to be on Trulicity during surgical screening, the medication should be discontinued entirely (not merely held) in consultation with the endocrinologist, and a glucose management plan that does not depend on GLP-1 receptor agonism should be established before the procedure date.

Patients on Dulaglutide for Cardiovascular Risk Reduction

The REWIND trial (N=9,901) established dulaglutide's cardiovascular benefit in patients with type 2 diabetes and established or high cardiovascular risk, showing a 12% relative risk reduction in major adverse cardiovascular events over a median 5.4 years [12]. Holding the drug for 7 days in this population does not meaningfully increase cardiovascular risk given the 5-day half-life and the short hold duration. The benefit is far outweighed by the aspiration hazard if the drug is continued through surgery.

Pediatric and Adolescent Patients

Dulaglutide is FDA-approved for use in patients aged 10 and older with type 2 diabetes [13]. Perioperative gastric ultrasound reference values differ in pediatric patients, and anesthesiologists with pediatric training should be consulted for this group.